| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AMR |
| Uniprot No | Q9Y4X0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-333aa |
| 氨基酸序列 | MAAGCCGVKKQKLSSSPPSGSGGGGGASSSSHCSGESQCRAGELGLGGAGTRLNGLGGLTGGGSGSGCTLSPPQGCGGGGGGIALSPPPSCGVGTLLSTPAAATSSSPSSSSAASSSSPGSRKMVVSAEMCCFCFDVLYCHLYGYQQPRTPRFTNEPYPLFVTWKIGRDKRLRGCIGTFSAMNLHSGLREYTLTSALKDSRFPPMTRDELPRLFCSVSLLTNFEDVCDYLDWEVGVHGIRIEFINEKGSKRTATYLPEVAKEQGWDHIQTIDSLLRKGGYKAPITNEFRKTIKLTRYRSEKMTLSYAEYLAHRQHHHFQNGIGHPLPPYNHYS |
| 预测分子量 | 35,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与AMR(抗微生物耐药性)相关的重组蛋白研究示例文献(注：部分文献为模拟示例，实际引用时请核实原文信息)：
---
1. **文献名称**：*Recombinant proteins for rapid detection of antimicrobial resistance in Gram-negative pathogens*
**作者**：Smith, J. et al.
**摘要**：该研究开发了一种基于大肠杆菌表达的重组融合蛋白生物传感器，用于快速检测革兰氏阴性菌的β-内酰胺酶活性。该蛋白通过结合荧光标记底物，可在30分钟内识别耐药菌株，为临床AMR快速诊断提供新工具。
---
2. **文献名称**：*Engineering recombinant ABC transporters to study multidrug resistance mechanisms*
**作者**：Chen, L. & Wang, H.
**摘要**：作者利用昆虫细胞表达系统重构了细菌ABC转运蛋白AcrB的重组体，通过体外功能实验揭示了该蛋白在主动外排抗生素中的作用机制，为针对外排泵的抑制剂设计提供结构基础。
---
3. **文献名称**：*A recombinant vaccine targeting AMR-associated biofilm formation in Staphylococcus aureus*
**作者**：Gupta, R. et al.
**摘要**：研究通过重组技术表达金黄色葡萄球菌的胞外多糖合成关键蛋白PIA，并验证其作为疫苗抗原的潜力。动物实验表明，该重组蛋白可显著抑制细菌生物膜形成并增强抗生素疗效。
---
4. **文献名称**：*CRISPR-based recombinant expression of AMR gene regulators in E. coli*
**作者**：Kim, S. et al.
**摘要**：利用CRISPR-Cas9技术构建了携带耐药基因调控因子的重组大肠杆菌模型，系统解析了耐药基因表达的动态调控网络，为AMR机制研究提供可控的体外平台。
---
(注：以上文献为示例，实际研究中请通过PubMed或Web of Science等数据库检索最新文献。)
Antimicrobial resistance (AMR) has emerged as a global health crisis, driven by the overuse and misuse of antibiotics, leading pathogens to evolve resistance mechanisms. Recombinant protein technology plays a pivotal role in addressing AMR by enabling the development of novel diagnostics, therapeutics, and vaccines. Recombinant proteins are engineered through genetic modification, where target genes are cloned into expression vectors and produced in host systems like *E. coli*, yeast, or mammalian cells. This approach allows large-scale production of specific proteins with high purity and consistency.
In the context of AMR, recombinant proteins are used to create advanced diagnostic tools, such as antigen-based rapid tests or biosensors, to detect resistant pathogens or resistance markers (e.g., β-lactamases). They also underpin therapeutic innovations, including engineered antibodies, antimicrobial peptides, and enzymes that degrade biofilms or neutralize toxins. For example, phage tail-like bacteriocins and lysins, produced recombinantly, show promise in targeting multidrug-resistant bacteria without affecting commensal flora. Additionally, recombinant vaccines targeting AMR pathogens (e.g., *Streptococcus pneumoniae*, *Neisseria gonorrhoeae*) are being explored to reduce antibiotic dependence.
Research into AMR-related recombinant proteins also focuses on understanding resistance mechanisms. Proteins like efflux pumps, modified penicillin-binding proteins, or enzymes involved in horizontal gene transfer (e.g., recombinases) are produced recombinantly to study their structures and functions, aiding in drug design. Challenges remain, such as optimizing expression systems for complex proteins, ensuring stability, and mitigating costs. However, advances in synthetic biology, AI-driven protein design, and high-throughput screening are accelerating progress. By integrating recombinant protein technology with multidisciplinary approaches, scientists aim to curb the spread of AMR and revitalize the efficacy of existing antimicrobial therapies.
×
